Prevention of heterotopic ossification after total hip replacement with NSAIDs

被引:63
|
作者
Fijn, R
Koorevaar, RT
Brouwers, JRBJ
机构
[1] Univ Groningen Inst Drug Explorat, Groningen Res Inst Pharm GRIP, NL-9713 AV Groningen, Netherlands
[2] Univ Groningen, Dept Social Pharm Pharmacoepidemiol & Pharmacothe, NL-9713 AV Groningen, Netherlands
[3] W Fries Gasthuis, Dept Clin Pharm, Hoorn, Netherlands
[4] Univ Nijmegen Hosp, Dept Orthopaed, NL-6500 HB Nijmegen, Netherlands
[5] Leeuwarden & Tjongerschans Hosp, Dept Clin Pharmacol, Leeuwarden Med Ctr, Heerenveen, Netherlands
[6] Leeuwarden & Tjongerschans Hosp, Dept Hosp Pharm, Leeuwarden Med Ctr, Heerenveen, Netherlands
来源
PHARMACY WORLD & SCIENCE | 2003年 / 25卷 / 04期
关键词
COX-2; inhibitors; diclofenac; heterotopic ossification (HO); indomethacin; naproxen; non-steroidal; anti-inflammatory drugs (NSAIDs); rofecoxib;
D O I
10.1023/A:1024830213832
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: non steroidal anti-inflammatory drugs ( NSAIDs) and prophylactic radiotherapy can prevent ectopic bone formation around the hip after total hip arthroplasty. Methods: We retrieved from Medline, Embase and the Cochrane Register ( clinical) trials and other relevant literature on the prevention of heterotopic ossification (HO) from 1990-2002 for further review. Results: Review of these clinical trials shows that HO is effectively prevented by a postoperative NSAID treatment with indomethacin for at least seven days. The best evidence is available for indomethacin, although naproxen, diclofenac and ibuprofen are also well documented. Short term use of ibuprofen is not effective. If NSAIDs are contraindicated, preoperative or postoperative radiotherapy is a very effective therapeutic option to prevent HO. Discussion and conclusion: Because of the potential of serious gastrointestinal side effects of NSAIDs and their interaction with anticoagulant drugs, rofecoxib and other COX-2 specific NSAIDs may be a safer option for the treatment of HO. However, randomised controlled studies are needed to confirm the results of the rofecoxib study.
引用
收藏
页码:138 / 145
页数:8
相关论文
共 50 条
  • [1] Prevention of heterotopic ossification after total hip replacement with NSAIDs
    R. Fijn
    R.Th. Koorevaar
    J.R.B.J. Brouwers
    Pharmacy World and Science, 2003, 25 : 138 - 145
  • [2] Naproxen in the prevention of heterotopic ossification after total hip replacement
    Vielpeau, C
    Joubert, JM
    Hulet, C
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1999, (369) : 279 - 288
  • [3] PREVENTION OF HETEROTOPIC OSSIFICATION (HO) AFTER TOTAL HIP-REPLACEMENT
    HEYD, R
    ADAMIETZ, LA
    RADIOTHERAPY AND ONCOLOGY, 1994, 30 (02) : 184 - 185
  • [4] IRRADIATION FOR THE PREVENTION OF PERIARTICULAR HETEROTOPIC OSSIFICATION AFTER TOTAL HIP-REPLACEMENT
    GOLDMANN, AR
    SEEGENSCHMIEDT, M
    ANDREAS, P
    HOHMANN, D
    SAUER, R
    BECK, H
    ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 1993, 131 (02): : 151 - 155
  • [5] PREVENTION OF HETEROTOPIC OSSIFICATION (HO) AFTER TOTAL HIP-REPLACEMENT - RESPONSE
    SEEGENSCHMIEDT, MH
    RADIOTHERAPY AND ONCOLOGY, 1994, 30 (02) : 185 - 186
  • [6] Prevention of heterotopic ossification after total hip replacement: a cost-effectiveness analysis
    Paix, A.
    Stevignon, T.
    Baudrier, N.
    Noel, G.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S891 - S892
  • [7] Determinants of heterotopic ossification after total hip replacement surgery
    Fransen, Marlene
    Neal, Bruce
    Cameron, Ian D.
    Crawford, Ross
    Tregonning, Garnet
    Winstanley, Julie
    Norton, Robyn
    HIP INTERNATIONAL, 2009, 19 (01) : 41 - 46
  • [8] Preliminary study of rofecoxib (25 mg) in prevention of heterotopic ossification after total hip replacement
    F. Franchin
    F. Sanguineti
    G. Caione
    Journal of Orthopaedics and Traumatology, 2004, 5 (2) : 77 - 80
  • [9] Heterotopic Ossification After Surface Replacement Arthroplasty and Total Hip Arthroplasty
    Rama, Krishna Reddi Boddu Siva
    Vendittoli, Pascal-Andre
    Ganapathi, Muthu
    Borgmann, Rene
    Roy, Alain
    Lavigne, Martin
    JOURNAL OF ARTHROPLASTY, 2009, 24 (02): : 256 - 262
  • [10] Heterotopic ossification after total hip arthroplasty: Risk factors and prevention
    Vastel, L
    Kerboull, L
    Anract, P
    Kerboull, M
    REVUE DU RHUMATISME, 1998, 65 (04): : 238 - 244